Status:
COMPLETED
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
Lead Sponsor:
ContraVir Pharmaceuticals, Inc.
Conditions:
Renal Impairment
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex
Detailed Description
This is a Phase 1 study to investigate the effects of Renal Impairment (mild, moderate and severe) on the pharmacokinetics of Tenofovir Exalidex
Eligibility Criteria
Inclusion
- Age: 18 years of age and over
- Capable of giving written informed consent
- Capable of completing study requirements
Exclusion
- Positive result for HIV, HBV, or HCV
- History or medical condition which could impact patient safety
- Current or past abuse of alcohol or drugs
- Participation in another clinical trial within the past 30 days
Key Trial Info
Start Date :
September 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 20 2018
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03284164
Start Date
September 28 2017
End Date
February 20 2018
Last Update
June 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Orlando Clinical Research Center
Orlando, Florida, United States, 32809